Nymox Pharmaceutical Corporation
NYMXF
$0.1364
$0.026424.00%
OTC PK
| 09/30/2024 | 12/31/2023 | 09/30/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 142.00K | 2.83M | 353.00K | 353.00K | 506.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 653.00K | 4.85M | 1.01M | 1.01M | 1.10M |
| Operating Income | -653.00K | -4.85M | -1.01M | -1.01M | -1.10M |
| Income Before Tax | -716.00K | -5.31M | -1.04M | -1.04M | -1.11M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -716.00K | -5.31M | -1.04M | -1.04M | -1.11M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -716.00K | -5.31M | -1.04M | -1.04M | -1.11M |
| EBIT | -653.00K | -4.85M | -1.01M | -1.01M | -1.10M |
| EBITDA | -652.70K | -4.85M | -1.01M | -1.01M | -1.10M |
| EPS Basic | -0.01 | -0.06 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | 0.00 | -0.03 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.01 | -0.06 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | 0.00 | -0.03 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 93.54M | 91.79M | 92.16M | 92.16M | 91.27M |
| Average Diluted Shares Outstanding | 93.54M | 91.79M | 92.16M | 92.16M | 91.27M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |